Clinical Trial Details
Braintumor Website

[Information provided by: ClinicalTrials.gov, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT00958841 : Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin
PhasePhase 2
AgesMin: 18 Years Max: N/A
Eligibility
Inclusion Criteria:

- Male and Female Patients at least 18 years old

- Patient who have rare tumors of neuroendocrine origin, such as tumors of the:

1. pancreas

2. pituitary glands

3. Nelson syndrome

4. ectopic-ACTH secreting tumor

- Patients who have failed standard of care treatment or for whom no standard of care
treatment exist

- Signed Informed Consent

Exclusion Criteria:

- Patients with active gallbladder disease

- Patients with any ongoing or planned anti-neoplastic or interferon therapy

- Poorly controlled diabetes mellitus

- Female patients who are pregnant or lactating, or are of childbearing potential and
not practicing a medically acceptable method of birth control

Other protocol-defined inclusion/exclusion criteria may apply.
LinksPermanent Link to THIS page: https://virtualtrials.com/nct/display1trial.cfm?nct=NCT00958841      |      Link to official Clinicaltrials.gov listing
Locations



Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740